{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:56:16Z","timestamp":1792504576375,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Neurosci"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1038\/s41593-020-00737-w","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T17:05:38Z","timestamp":1605546338000},"page":"1580-1588","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life"],"prefix":"10.1038","volume":"23","author":[{"given":"Ruth E.","family":"Uhlmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rother","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Schelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Ullrich Gavilanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4665-7203","authenticated-orcid":false,"given":"Sarah K.","family":"Fritschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Buehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelos","family":"Skodras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawaa","family":"Al-Shaana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Beschorner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-7359","authenticated-orcid":false,"given":"Lan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Kaeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Oberm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Kartberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Stavenhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Ulrich","family":"Rahfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6655-7539","authenticated-orcid":false,"given":"Holger","family":"Cynis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0802-0052","authenticated-orcid":false,"given":"Paul H.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6818-4876","authenticated-orcid":false,"given":"Thierry","family":"Bussiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9166-3261","authenticated-orcid":false,"given":"Lary C.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Staufenbiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-1072","authenticated-orcid":false,"given":"Mathias","family":"Jucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"737_CR1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack, C. R. Jr et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"737_CR2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long, J. M. & Holtzman, D. M. Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179, 312\u2013339 (2019).","journal-title":"Cell"},{"key":"737_CR3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.25410","volume":"85","author":"F Panza","year":"2019","unstructured":"Panza, F., Lozupone, M., Seripa, D. & Imbimbo, B. P. Amyloid-\u03b2 immunotherapy for Alzheimer disease: is it now a long shot? Ann. Neurol. 85, 303\u2013315 (2019).","journal-title":"Ann. Neurol."},{"key":"737_CR4","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","volume":"91","author":"E McDade","year":"2018","unstructured":"McDade, E. et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology 91, e1295\u2013e1306 (2018).","journal-title":"Neurology"},{"key":"737_CR5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","volume":"14","author":"VL Villemagne","year":"2018","unstructured":"Villemagne, V. L., Dor\u00e9, V., Burnham, S. C., Masters, C. L. & Rowe, C. C. Imaging tau and amyloid-\u03b2 proteinopathies in Alzheimer disease and other conditions. Nat. Rev. Neurol. 14, 225\u2013236 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"737_CR6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/547153a","volume":"547","author":"E McDade","year":"2017","unstructured":"McDade, E. & Bateman, R. J. Stop Alzheimer\u2019s before it starts. Nature 547, 153\u2013155 (2017).","journal-title":"Nature"},{"key":"737_CR7","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/brain\/aww015","volume":"139","author":"S Palmqvist","year":"2016","unstructured":"Palmqvist, S., Mattsson, N. & Hansson, O. Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography. Brain 139, 1226\u20131236 (2016).","journal-title":"Brain"},{"key":"737_CR8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00401-018-1897-9","volume":"136","author":"DR Thal","year":"2018","unstructured":"Thal, D. R. et al. Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid \u03b2-protein deposition. Acta Neuropathol. 136, 557\u2013567 (2018).","journal-title":"Acta Neuropathol."},{"key":"737_CR9","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000005354","volume":"90","author":"SM Landau","year":"2018","unstructured":"Landau, S. M., Horng, A. & Jagust, W. J. Memory decline accompanies subthreshold amyloid accumulation. Neurology 90, e1452\u2013e1460 (2018).","journal-title":"Neurology"},{"key":"737_CR10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","volume":"15","author":"R La Joie","year":"2019","unstructured":"La Joie, R. et al. Multisite study of the relationships between antemortem [11C]PIB-PET centiloid values and postmortem measures of Alzheimer\u2019s disease neuropathology. Alzheimers Dement. 15, 205\u2013216 (2019).","journal-title":"Alzheimers Dement."},{"key":"737_CR11","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.15252\/embr.201744067","volume":"18","author":"L Ye","year":"2017","unstructured":"Ye, L. et al. A\u03b2 seeding potency peaks in the early stages of cerebral \u03b2\u2010amyloidosis. EMBO Rep. 18, 1536\u20131544 (2017).","journal-title":"EMBO Rep."},{"key":"737_CR12","doi-asserted-by":"crossref","first-page":"eaat8462","DOI":"10.1126\/scitranslmed.aat8462","volume":"11","author":"A Aoyagi","year":"2019","unstructured":"Aoyagi, A. et al. A\u03b2 and tau prion-like activities decline with longevity in the Alzheimer\u2019s disease human brain. Sci. Transl. Med. 11, eaat8462 (2019).","journal-title":"Sci. Transl. Med."},{"key":"737_CR13","unstructured":"Fuller, J. P., Stavenhagen, J. B. & Teeling, J. L. New roles for Fc receptors in neurodegeneration: the impact on immunotherapy for Alzheimer\u2019s disease. Front. Neurosci. 8, 235 (2014)."},{"key":"737_CR14","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1126\/science.1131864","volume":"313","author":"M Meyer-Luehmann","year":"2006","unstructured":"Meyer-Luehmann, M. et al. Exogenous induction of cerebral \u03b2-amyloidogenesis is governed by agent and host. Science 313, 1781\u20131784 (2006).","journal-title":"Science"},{"key":"737_CR15","doi-asserted-by":"crossref","first-page":"10264","DOI":"10.1523\/JNEUROSCI.1608-14.2014","volume":"34","author":"YS Eisele","year":"2014","unstructured":"Eisele, Y. S. et al. Multiple factors contribute to the peripheral induction of cerebral \u03b2-amyloidosis. J. Neurosci. 34, 10264\u201310273 (2014).","journal-title":"J. Neurosci."},{"key":"737_CR16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.neuroscience.2006.08.027","volume":"143","author":"A G\u00fcntert","year":"2006","unstructured":"G\u00fcntert, A., D\u00f6beli, H. & Bohrmann, B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143, 461\u2013475 (2006).","journal-title":"Neuroscience"},{"key":"737_CR17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ajpath.2013.05.005","volume":"183","author":"JL Frost","year":"2013","unstructured":"Frost, J. L. et al. Pyroglutamate-3 amyloid-\u03b2 deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am. J. Pathol. 183, 369\u2013381 (2013).","journal-title":"Am. J. Pathol."},{"key":"737_CR18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/brain\/awt362","volume":"137","author":"A Rijal Upadhaya","year":"2014","unstructured":"Rijal Upadhaya, A. et al. Biochemical stages of amyloid-\u03b2 peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer\u2019s disease. Brain 137, 887\u2013903 (2014).","journal-title":"Brain"},{"key":"737_CR19","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/nn.4117","volume":"18","author":"L Ye","year":"2015","unstructured":"Ye, L. et al. Persistence of A\u03b2 seeds in APP null mouse brain. Nat. Neurosci. 18, 1559\u20131561 (2015).","journal-title":"Nat. Neurosci."},{"key":"737_CR20","unstructured":"Arndt, J. W. et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2. Sci. Rep. 8, 6412 (2018)."},{"key":"737_CR21","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1021\/cb4000376","volume":"8","author":"S Nystr\u00f6m","year":"2013","unstructured":"Nystr\u00f6m, S. et al. Evidence for age-dependent in vivo conformational rearrangement within A\u03b2 amyloid deposits. ACS Chem. Biol. 8, 1128\u20131133 (2013).","journal-title":"ACS Chem. Biol."},{"key":"737_CR22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","volume":"91","author":"M Bacioglu","year":"2016","unstructured":"Bacioglu, M. et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91, 56\u201366 (2016).","journal-title":"Neuron"},{"key":"737_CR23","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/0092-8674(93)90635-4","volume":"73","author":"JT Jarrett","year":"1993","unstructured":"Jarrett, J. T. & Lansbury, P. T. Jr. Seeding \u2018one-dimensional crystallization\u2019 of amyloid: a pathogenic mechanism in Alzheimer\u2019s disease and scrapie? Cell 73, 1055\u20131058 (1993).","journal-title":"Cell"},{"key":"737_CR24","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.cell.2012.02.022","volume":"148","author":"D Eisenberg","year":"2012","unstructured":"Eisenberg, D. & Jucker, M. The amyloid state of proteins in human diseases. Cell 148, 1188\u20131203 (2012).","journal-title":"Cell"},{"key":"737_CR25","doi-asserted-by":"crossref","first-page":"14488","DOI":"10.1523\/JNEUROSCI.3088-11.2011","volume":"31","author":"F Langer","year":"2011","unstructured":"Langer, F. et al. Soluble A\u03b2 seeds are potent inducers of cerebral \u03b2-amyloid deposition. J. Neurosci. 31, 14488\u201314495 (2011).","journal-title":"J. Neurosci."},{"key":"737_CR26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/bpa.12734","volume":"30","author":"N Katzmarski","year":"2020","unstructured":"Katzmarski, N. et al. A\u03b2 oligomers trigger and accelerate A\u03b2 seeding. Brain Pathol. 30, 36\u201345 (2020).","journal-title":"Brain Pathol."},{"key":"737_CR27","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1074\/jbc.RA118.006604","volume":"294","author":"W Michno","year":"2019","unstructured":"Michno, W. et al. Pyroglutamation of amyloid-\u03b2x-42 (A\u03b2x-42) followed by A\u03b21-40 deposition underlies plaque polymorphism in progressing Alzheimer\u2019s disease pathology. J. Biol. Chem. 294, 6719\u20136732 (2019).","journal-title":"J. Biol. Chem."},{"key":"737_CR28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nature11060","volume":"485","author":"JM Nussbaum","year":"2012","unstructured":"Nussbaum, J. M. et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-\u03b2. Nature 485, 651\u2013655 (2012).","journal-title":"Nature"},{"key":"737_CR29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537, 50\u201356 (2016).","journal-title":"Nature"},{"key":"737_CR30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00401-015-1484-2","volume":"130","author":"JP Fuller","year":"2015","unstructured":"Fuller, J. P. et al. Comparing the efficacy and neuroinflammatory potential of three anti-Abeta antibodies. Acta Neuropathol. 130, 699\u2013711 (2015).","journal-title":"Acta Neuropathol."},{"key":"737_CR31","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB DeMattos","year":"2012","unstructured":"DeMattos, R. B. et al. A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice. Neuron 76, 908\u2013920 (2012).","journal-title":"Neuron"},{"key":"737_CR32","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","volume":"21","author":"M Jucker","year":"2018","unstructured":"Jucker, M. & Walker, L. C. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat. Neurosci. 21, 1341\u20131349 (2018).","journal-title":"Nat. Neurosci."},{"key":"737_CR33","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.1078259","volume":"298","author":"M Pfeifer","year":"2002","unstructured":"Pfeifer, M. et al. Cerebral hemorrhage after passive anti-A\u03b2 immunotherapy. Science 298, 1379 (2002).","journal-title":"Science"},{"key":"737_CR34","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1093\/brain\/awn261","volume":"131","author":"D Boche","year":"2008","unstructured":"Boche, D. et al. Consequence of A\u03b2 immunization on the vasculature of human Alzheimer\u2019s disease brain. Brain 131, 3299\u20133310 (2008).","journal-title":"Brain"},{"key":"737_CR35","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement. 7, 367\u2013385 (2011).","journal-title":"Alzheimers Dement."},{"key":"737_CR36","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12683-8","volume":"10","author":"M Kollmer","year":"2019","unstructured":"Kollmer, M. et al. Cryo-EM structure and polymorphism of A\u03b2 amyloid fibrils purified from Alzheimer\u2019s brain tissue. Nat. Commun. 10, 4760 (2019).","journal-title":"Nat. Commun."},{"key":"737_CR37","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1523\/JNEUROSCI.4560-08.2009","volume":"29","author":"RA Karlnoski","year":"2009","unstructured":"Karlnoski, R. A. et al. Suppression of amyloid deposition leads to long-term reductions in Alzheimer\u2019s pathologies in Tg2576 mice. J. Neurosci. 29, 4964\u20134971 (2009).","journal-title":"J. Neurosci."},{"key":"737_CR38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1326-7-39","volume":"7","author":"P Das","year":"2012","unstructured":"Das, P. et al. Transient pharmacologic lowering of A\u03b2 production prior to deposition results in sustained reduction of amyloid plaque pathology. Mol. Neurodegener. 7, 39 (2012).","journal-title":"Mol. Neurodegener."},{"key":"737_CR39","doi-asserted-by":"crossref","first-page":"7606","DOI":"10.1039\/C4CP05563B","volume":"17","author":"P Arosio","year":"2015","unstructured":"Arosio, P., Knowles, T. P. J. & Linse, S. On the lag phase in amyloid fibril formation. Phys. Chem. Chem. Phys. 17, 7606\u20137618 (2015).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"737_CR40","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","volume":"70","author":"H Braak","year":"2011","unstructured":"Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960\u2013969 (2011).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"737_CR41","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/WNN.0000000000000071","volume":"28","author":"O Pletnikova","year":"2015","unstructured":"Pletnikova, O. et al. Alzheimer lesions in the autopsied brains of people 30 to 50 years of age. Cogn. Behav. Neurol. 28, 144\u2013152 (2015).","journal-title":"Cogn. Behav. Neurol."},{"key":"737_CR42","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","volume":"84","author":"RA Sperling","year":"2014","unstructured":"Sperling, R. A., Mormino, E. & Johnson, K. The evolution of preclinical Alzheimer\u2019s disease: implications for prevention trials. Neuron 84, 608\u2013622 (2014).","journal-title":"Neuron"},{"key":"737_CR43","doi-asserted-by":"crossref","first-page":"a024323","DOI":"10.1101\/cshperspect.a024323","volume":"8","author":"GT Westermark","year":"2018","unstructured":"Westermark, G. T., F\u00e4ndrich, M., Lundmark, K. & Westermark, P. Noncerebral amyloidoses: aspects on seeding, cross-seeding, and transmission. Cold Spring Harb. Perspect. Med. 8, a024323 (2018).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"737_CR44","first-page":"194re2","volume":"5","author":"LF Maia","year":"2013","unstructured":"Maia, L. F. et al. Changes in amyloid-\u03b2 and tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci. Transl. Med. 5, 194re2 (2013).","journal-title":"Sci. Transl. Med."},{"key":"737_CR45","doi-asserted-by":"crossref","first-page":"895","DOI":"10.15252\/emmm.201505026","volume":"7","author":"LF Maia","year":"2015","unstructured":"Maia, L. F. et al. Increased CSF A\u03b2 during the very early phase of cerebral A\u03b2 deposition in mouse models. EMBO Mol. Med. 7, 895\u2013903 (2015).","journal-title":"EMBO Mol. Med."},{"key":"737_CR46","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1126\/science.1194516","volume":"330","author":"YS Eisele","year":"2010","unstructured":"Eisele, Y. S. et al. Peripherally applied A\u03b2-containing inoculates induce cerebral \u03b2-amyloidosis. Science 330, 980\u2013982 (2010).","journal-title":"Science"},{"key":"737_CR47","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/nm.3734","volume":"20","author":"FC Maier","year":"2014","unstructured":"Maier, F. C. et al. Longitudinal PET-MRI reveals \u03b2-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. Nat. Med. 20, 1485\u20131492 (2014).","journal-title":"Nat. Med."},{"key":"737_CR48","doi-asserted-by":"crossref","first-page":"13287","DOI":"10.1073\/pnas.94.24.13287","volume":"94","author":"C Sturchler-Pierrat","year":"1997","unstructured":"Sturchler-Pierrat, C. et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl Acad. Sci. USA 94, 13287\u201313292 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"737_CR49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann, B. et al. Gantenerumab: a novel human anti-A\u03b2 antibody demonstrates sustained cerebral amyloid-\u03b2 binding and elicits cell-mediated removal of human amyloid-\u03b2. J. Alzheimers Dis. 28, 49\u201369 (2012).","journal-title":"J. Alzheimers Dis."},{"key":"737_CR50","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","volume":"98","author":"RB DeMattos","year":"2001","unstructured":"DeMattos, R. B. et al. Peripheral anti-A\u03b2 antibody alters CNS and plasma A\u03b2 clearance and decreases brain A\u03b2 burden in a mouse model of Alzheimer\u2019s disease. Proc. Natl Acad. Sci. USA 98, 8850\u20138855 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"737_CR51","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","volume":"32","author":"O Adolfsson","year":"2012","unstructured":"Adolfsson, O. et al. An effector-reduced anti-\u03b2-amyloid (A\u03b2) antibody with unique A\u03b2 binding properties promotes neuroprotection and glial engulfment of A\u03b2. J. Neurosci. 32, 9677\u20139689 (2012).","journal-title":"J. Neurosci."},{"key":"737_CR52","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/(SICI)1097-4547(19961101)46:3<283::AID-JNR1>3.0.CO;2-G","volume":"46","author":"PA Paganetti","year":"1996","unstructured":"Paganetti, P. A., Lis, M., Klafki, H. W. & Staufenbiel, M. Amyloid precursor protein truncated at any of the \u03b3-secretase sites is not cleaved to \u03b2-amyloid. J. Neurosci. Res. 46, 283\u2013293 (1996).","journal-title":"J. Neurosci. Res."},{"key":"737_CR53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1471-4159.2002.00889.x","volume":"81","author":"RB DeMattos","year":"2002","unstructured":"DeMattos, R. B. et al. Plaque-associated disruption of CSF and plasma amyloid-\u03b2 (A\u03b2) equilibrium in a mouse model of Alzheimer\u2019s disease. J. Neurochem. 81, 229\u2013236 (2002).","journal-title":"J. Neurochem."},{"key":"737_CR54","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1523\/JNEUROSCI.21-05-01619.2001","volume":"21","author":"DT Winkler","year":"2001","unstructured":"Winkler, D. T. et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J. Neurosci. 21, 1619\u20131627 (2001).","journal-title":"J. Neurosci."},{"key":"737_CR55","doi-asserted-by":"crossref","first-page":"13018","DOI":"10.1073\/pnas.1713215114","volume":"114","author":"J Rasmussen","year":"2017","unstructured":"Rasmussen, J. et al. Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer\u2019s disease. Proc. Natl Acad. Sci. USA 114, 13018\u201313023 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"737_CR56","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.25562","volume":"86","author":"J Schelle","year":"2019","unstructured":"Schelle, J. et al. Early A\u03b2 reduction prevents progression of cerebral amyloid angiopathy. Ann. Neurol. 86, 561\u2013571 (2019).","journal-title":"Ann. Neurol."},{"key":"737_CR57","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0076-6879(06)12003-0","volume":"412","author":"SN Bagriantsev","year":"2006","unstructured":"Bagriantsev, S. N., Kushnirov, V. V. & Liebman, S. W. Analysis of amyloid aggregates using agarose gel electrophoresis. Methods Enzymol. 412, 33\u201348 (2006).","journal-title":"Methods Enzymol."},{"key":"737_CR58","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische, O. et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat. Med. 25, 277\u2013283 (2019).","journal-title":"Nat. Med."}],"container-title":["Nature Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41593-020-00737-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41593-020-00737-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41593-020-00737-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:20:15Z","timestamp":1684621215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41593-020-00737-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,16]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["737"],"URL":"https:\/\/doi.org\/10.1038\/s41593-020-00737-w","relation":{},"ISSN":["1097-6256","1546-1726"],"issn-type":[{"value":"1097-6256","type":"print"},{"value":"1546-1726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,16]]},"assertion":[{"value":"11 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.C., F.K. and J.B.S. are current or former employees of Lundbeck. F.Q., P.H.W. and T.B. are current employees and\/or shareholders of Biogen. J.-U.R and H.C. are former employees of Probiodrug AG; M.S. is a former employee of Novartis. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}